## Nobuhisa Yoshikawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1755186/publications.pdf

Version: 2024-02-01

623574 610775 14 54 754 24 citations g-index h-index papers 56 56 56 1075 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Endometriosis and cancer. Free Radical Biology and Medicine, 2019, 133, 186-192.	1.3	94
2	ALX1 Induces Snail Expression to Promote Epithelial-to-Mesenchymal Transition and Invasion of Ovarian Cancer Cells. Cancer Research, 2013, 73, 1581-1590.	0.4	58
3	Oxidative stress-dependent and -independent death of glioblastoma cells induced by non-thermal plasma-exposed solutions. Scientific Reports, 2019, 9, 13657.	1.6	48
4	Plasma-activated medium promotes autophagic cell death along with alteration of the mTOR pathway. Scientific Reports, 2020, 10, 1614.	1.6	42
5	PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Letters, 2019, 442, 181-192.	3.2	41
6	CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway. Clinical and Experimental Metastasis, 2020, 37, 145-158.	1.7	37
7	Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. American Journal of Obstetrics and Gynecology, 2018, 219, 385.e1-385.e7.	0.7	36
8	PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncology Reports, 2016, 35, 2543-2552.	1.2	27
9	Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy. Cancers, 2021, 13, 1141.	1.7	23
10	Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan. Lancet Infectious Diseases, The, 2016, 16, 1325.	4.6	21
11	Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in Japanese women. Journal of Gynecologic Oncology, 2014, 25, 118.	1.0	20
12	Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF- $\hat{l}^2$ 1/thrombospondin-1 axis. Matrix Biology, 2022, 109, 70-90.	1.5	19
13	A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-Î <sup>2</sup> derived from ovarian cancer. Oncology Reports, 2017, 39, 193-200.	1.2	18
14	Adjusted multiple gases in the plasma flow induce differential antitumor potentials of plasmaâ€activated solutions. Plasma Processes and Polymers, 2020, 17, 1900259.	1.6	17
15	The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. Oncotarget, 2018, 9, 6298-6307.	0.8	17
16	Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. Journal of Gynecologic Oncology, 2019, 30, e85.	1.0	15
17	Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance. Oncogene, 2021, 40, 1255-1268.	2.6	14
18	Survival impact of capsule status in stage I ovarian mucinous carcinomaâ€"A mulicentric retrospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 234, 131-136.	0.5	13

#	Article	IF	CITATIONS
19	The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus. Oncology Letters, 2018, 16, 515-521.	0.8	11
20	Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary. International Journal of Gynecological Cancer, 2019, 29, 910-915.	1.2	11
21	Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~. BMC Cancer, 2019, 19, 1235.	1.1	11
22	The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer. International Journal of Clinical Oncology, 2020, 25, 384-390.	1.0	11
23	The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma. Scientific Reports, 2020, 10, 7135.	1.6	11
24	Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age. International Journal of Clinical Oncology, 2020, 25, 187-194.	1.0	10
25	Sarcopenia as a Predictor of Survival Among Patients With Organ Metastatic Cervical Cancer. Nutrition in Clinical Practice, 2020, 35, 1041-1046.	1.1	10
26	The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma. Journal of Gynecologic Oncology, 2020, 31, e47.	1.0	10
27	Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis, 2019, 40, 1435-1444.	1.3	9
28	Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma. International Journal of Clinical Oncology, 2019, 24, 950-956.	1.0	8
29	Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer. In Vivo, 2020, 34, 109-116.	0.6	8
30	Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy. Case Reports in Oncology, 2020, 13, 373-378.	0.3	7
31	Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database. Nagoya Journal of Medical Science, 2019, 81, 193-198.	0.6	7
32	Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. Oncology Reports, 2019, 42, 2323-2332.	1.2	7
33	Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma. Archives of Gynecology and Obstetrics, 2019, 300, 717-724.	0.8	6
34	Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer. Current Oncology, 2021, 28, 1663-1672.	0.9	6
35	Interleukinâ€'33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis. International Journal of Oncology, 2019, 55, 755-765.	1.4	5
36	Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 4, 100071.	0.6	5

#	Article	IF	CITATIONS
37	The Therapeutic Effects of Goreisan, a Traditional Japanese Herbal Medicine, on Lower-Limb Lymphedema after Lymphadenectomy in Gynecologic Malignancies: A Case Series Study. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-6.	0.5	5
38	The Prognostic Significance of Peritumoral Lymphocytes' Band-like Structure in Type II Endometrial Cancer. Anticancer Research, 2021, 41, 249-258.	0.5	4
39	Is adjuvant chemotherapy necessary for young women with early-stage epithelial ovarian cancer who have undergone fertility-sparing surgery?: a multicenter retrospective analysis. BMC Women's Health, 2022, 22, 80.	0.8	4
40	Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy. Scientific Reports, 2022, 12, 4513.	1.6	4
41	Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?. International Journal of Clinical Oncology, 2019, 24, 567-574.	1.0	3
42	Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary. Oncotarget, 2018, 9, 27564-27573.	0.8	3
43	Obesity contributes to the stealth peritoneal dissemination of ovarian cancer: a multiâ€institutional retrospective cohort study. Obesity, 0, , .	1.5	3
44	Relationship between preexisting mental disorders and prognosis of gynecologic cancers: A case–control study. Journal of Obstetrics and Gynaecology Research, 2019, 45, 2082-2087.	0.6	2
45	A uterine pseudotumor of immunoglobulin <scp>G4</scp> â€related disease. Journal of Obstetrics and Gynaecology Research, 2021, 47, 430-435.	0.6	2
46	Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer. Cancer Cell International, 2021, 21, 314.	1.8	2
47	Is cystectomy an option as conservative surgery for young patients with borderline ovarian tumor? A multiâ€institutional retrospective study. International Journal of Gynecology and Obstetrics, 2022, 157, 437-443.	1.0	2
48	Survival after Anticancer Treatment of Terminally III Patients with Ovarian Carcinoma. Journal of Palliative Medicine, 2020, 23, 1060-1065.	0.6	2
49	Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?. International Journal of Clinical Oncology, 2022, 27, 609-618.	1.0	2
50	Does uterine preservation affect survival outcomes of patients with stage I ovarian sex cord-stromal cell tumours? A multi-institutional study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 52-56.	0.5	1
51	Establishment of a patientâ€derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary. Journal of Obstetrics and Gynaecology Research, 2021, 47, 713-719.	0.6	1
52	Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study. Journal of Gynecologic Oncology, 2022, 33, .	1.0	1
53	Is standard radical surgery necessary for elderly patients with early-stage epithelial ovarian carcinoma? ~Propensity score matched analysis~. Japanese Journal of Clinical Oncology, 2020, 50, 411-418.	0.6	0
54	Long-term post-recurrence survival outcomes in young women receiving fertility-sparing surgery for epithelial ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 267, 221-225.	0.5	0